Phase 3
Completed N=69
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
Source: ClinicalTrials.gov NCT04599465 ↗Enrolled (actual)
69
Serious AEs
8.7%
Results posted
Aug 2023
Primary outcomePrimary: Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48 — -35.0 milligrams per deciliter (mg/dl)
◆ Published Evidence
Emerging
5citations · ~5 / year
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.
Summary
This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function mutation (F/MF genotypes), with abnormal glucose metabolism.
Linked Publications
-
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48 |
-35.0 | — |
| SECONDARY Percentage of Participants With Improvement in Dysglycemia Categorization at Week 48 |
37.7 | — |
| SECONDARY Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) |
67; 6 | — |
Eligibility Criteria
Key Inclusion Criteria
- Heterozygous for F508del and an MF mutation (F/MF genotypes)
- Forced expiratory volume in 1 second (FEV1) value ≥ 30% of predicted mean for age, sex, and height
- Abnormal glucose tolerance determined by an OGTT as either:
- Impaired glucose tolerance (IGT) defined as 2 hour post OGTT blood glucose level ≥140 to <200 mg/dL (≥7.77 to <11.10 mmol/L) and fasting blood glucose level <126 mg/dL (<7.00 mmol/L)
- CF-related diabetes (CFRD) defined as either fasting hyperglycemia (blood glucose level ≥126 mg/dL [≥7.00 mmol/L] after an 8-hour fast) or 2-hour post OGTT blood glucose level ≥200 mg/dL (≥11.10 mmol/L)
Key Exclusion Criteria
- Clinically significant liver cirrhosis with or without portal hypertension
- Solid organ or hematological transplantation
- Lung infection with organisms associated with a more rapid decline in pulmonary status
- Type 1 or Type 2 diabetes
- Duration of CFRD ≥5 years
Other protocol defined Inclusion/Exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT04599465) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.